Despite some studies assessing antiepileptic drug usage patterns in single-centre settings, there was a lack of consensus regarding usage patterns, drug choices for various seizure types, and the sociodemographic and clinical factors that influence treatment decisions in India. So, this current survey-based study was intended to gather expert opinions regarding the clinical use of anti-epileptic drugs with a special focus on levetiracetam for the management of epilepsy in Indian settings. A questionnaire-based cross-sectional study involving 25 questions collected perspectives of experts across India regarding the prescription practice of anti-epileptic drugs for epilepsy management. It was noted that majority of the responders (85.93% of 192 experts) stated levetiracetam as a preferred therapeutic option for patients with newly diagnosed epilepsy. Levetiracetam 1000 mg/day was the frequently recommended dosage for such patients in clinical practice (66%). Approximately 76% of the experts suggested that patients receiving the drug might experience behavioural changes. About 49% and 82% of responders recommended levetiracetam for treating resistant epilepsy and pregnant epilepsy respectively. Nearly 62% of the clinicians recommended levetiracetam for paediatric patients with partial seizures over other antiepileptic drugs. Levetiracetam and brivaracetam were both rated as beneficial for treating epileptic patients by 50% of clinicians. Levetiracetam was rated as being more effective than brivaracetam by 28% of clinicians, while brivaracetam was rated as being more effective by 14% of clinicians. Hence, this consensus among clinician’s highlights levetiracetam as the preferred antiepileptic medication for the management of patients with recently diagnosed epilepsy. This recommendation extends patients with refractory epilepsy, pregnant subjects with epilepsy, and young children experiencing partial seizures, where the majority of the clinicians endorse levetiracetam over alternative antiepileptic medications. Both levetiracetam and brivaracetam offer comparable treatment benefits for patients with epilepsy.

The world of science, technology, engineering and medicine are today in the vast and visionary path of innovations and discoveries. The ailment of schizophrenia ailment and other neurodegenerative disorders in the similar vision are today in the midst of a deep crevice of scientific and medical introspection and ingenuity. The author is suffering from schizophrenia from the year 1993. Long years have passed since then and the suffering is immense and arduous. Since October 2012, the author is diagnosed with glaucoma in his both eyes. In this article the author deeply elucidates the vast and varied suffering, trials and tribulations of life and the needs of care and support from parents, relatives and doctors. Today is the world of Fourth Industrial Revolution and Internet 4.0. The ardor, the immense agony within the patient is elucidated in this article. Surely a newer and remarkable dawn in the science of neurodegenerative ailments and treatment will emerge if man and mankind takes positive and sound steps in the futuristic vision of the treatment of bipolar disorders and the vast world of schizophrenia.

Science, technology, engineering and medicine are today in the groundbreaking path of scientific steadfastness and scientific alacrity. The futuristic vision of biomedical science and neuroscience are today in the path of rejuvenation as United Nations Sustainable Development Goals reframes the path of human civilization. The author is suffering from schizophrenia since 1993. Long years have passed since then. The struggle, hardship and tribulations are immense in the path of life. This article is a deep introspection into the field of schizophrenia, neuroscience and biomedical science. This treatise is a deep message to all the sufferers of this difficult ailment of schizophrenia. The march of medical science and health science are in the path of newer divination and scientific revelation. Human civilization is treading ahead as regards scientific strides in the vast world of neuroscience. The author deeply reiterates the need of psychotherapy and counseling of the patients with schizophrenia. A greater scientific emancipation and scientific introspection are the needs of the hour. Thus the author deeply portrays the needs of biomedical science and the vast and visionary world of neuroscience in the futuristic envisioning of global research and development initiatives.

Objective: To gather expert opinions and insights on the prevalence of anxiety and depression, along with prescription trends for different therapeutic options based on escitalopram, in Indian outpatient settings. Methodology: The questionnaire-based survey, comprising 28 questions, collected perspectives of experts across India regarding the prescription practice of selective serotonin reuptake inhibitors (SSRIs) with a special focus on escitalopram for treating major depressive disorder. Additionally, information on the symptoms of major depressive disorder and the age range of those affected by the disorder was also collected. Results: About 53% of the 331 participants reported that behavioral symptoms were the most frequent among depressed patients. Among the various classes of antidepressants, about 86% of the participants indicated SSRIs as their preferred choice for treating depression. In comparison to vilazodone, paroxetine, and sertraline medications, approximately 87% of the respondents favored escitalopram as the ideal option for treating depression. According to 64% of the respondents, the use of escitalopram has led to improvements in 50-75% of patients. Around 74% of the respondents reported a significant correlation between early responders to antidepressant therapies and achieving full remission. About 49% stated that it may take 8 weeks for depressive patients undergoing escitalopram therapy to experience remission. Adverse effects and poor response were highlighted as the reasons for depressive patients transitioning from other SSRI medications to escitalopram by approximately 43% of the respondents. Conclusion: The survey emphasizes the significance of the 8-week regimen of escitalopram in achieving full remission in patients with depression. The majority of respondents underscored the superiority of escitalopram among SSRIs when compared to other options like vilazodone, paroxetine, and sertraline, reaffirming its role as a preferred choice for effective depression treatment.

The world of challenges in the field of medical science, biomedical science, health sciences and engineering are in the path of newer scientific and technological regeneration. In the similar vision, the science of psychology and psychiatry are also in the avenues of deep scientific ingenuity and scientific prowess. This is a case study of the author who is suffering from schizophrenia from November, 1993. Since October, 2012, he is diagnosed with glaucoma in his both eyes. Long years of agony, ardor, trials and tribulations have passed since then. This treatise deeply elucidates the strong ardor and mental health challenges faced by the author since November, 1993. Medical science, health science and technology needs to be revamped and re-envisioned as regards treatment and cure of this difficult mental health illness. The author deeply pronounces the needs of psychotherapy and counselling in the treatment and well-being of the patient. This article reiterates the revamping of the science of paranoid schizophrenia since this is an incurable ailment. Scientific rejuvenation and deep technological vision are the utmost needs of the hour. The field of biomedical sciences and biological engineering will truly open newer windows of scientific innovation and scientific triumph in decades to come. This article is a message to all sufferers of the ailment of schizophrenia and other bi-polar disorders. Surely a newer day and a newer dawn in medical science will emerge if discoveries and innovations moves towards positive directions in treatment and cure. Civilization and science will surely usher in a newer dawn in the science of psychiatry if there is an effective support system from doctors and psychologists across the globe. In the similar vision the domain of healthcare system across the world will witness newer scientific regeneration if researchers, scientists, students and policy makers takes affirmative steps and affirmative vision in the scientific research pursuit in psychological science in decades to come. Recent breakthroughs in cognitive science and neuroscience will surely usher in newer dimensions in treatment and cure of schizophrenia.